Alpha Teknova, Inc. · NASDAQ:TKNO
Alpha Teknova — FY2021 Earnings Presentation
18 slides from Alpha Teknova's earnings presentation, Mar 15, 2022
Slide 1: Q4 and Full Year 2021 Financial Results Slide Supplement
Q4 and Full Year 2021 Financial Results Slide Supplement Nasdaq: TKNO March 15, 2022
Slide 2: Today's Agenda
Today’s Agenda 1. Welcome 2. Business Highlights & Updates — Stephen Gunstream, President and CEO 3. Financial Results & 2022 Guidance — Matt Lowell, CFO 4. Q&A 2
Slide 3: Forward-Looking Statements and Use of Non-GAAP Financial Measures
Forward-Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements relating to our financ
Slide 4: Business Highlights & Updates
Business Highlights & Updates Stephen Gunstream, President and CEO
Slide 5: 2021 Highlights
2021 Highlights – Delivered full-year revenue growth of 31% y/y, ex-ST • Lab Essentials up 28% y/y – +18% y/y increase in average revenue per active customer • Clinical Solutions up 41% y/y – Active clinical customers increased to 22 in 2021 from 12 in 2020 – Advanced construction of new manufacturi
Slide 6: 2022 Outlook
2022 Outlook 2022 Revenue Guidance 2022 Investment Priorities – $44-48 million – Increase current capacity and • 30% growth y/y at the mid-point bring new manufacturing excluding Sample Transport facility online by year-end – Build out commercial and Total Revenue ($M) Guidance $44.0-48.0* marketing
Slide 7: Q4 and Full Year 2021 Financial Results and 2022 Outlook
Q4 and Full Year 2021 Financial Results and 2022 Outlook Matt Lowell, CFO
Slide 8: Q4:2021 Revenue Highlights
Q4:2021 Revenue Highlights Revenue by Category ($M) Key Highlights $10.2 $10.1 Total revenue in line y/y $2.4 Total revenue of $9.6 million, excluding $1.7 Sample Transport, up 26% y/y Lab Essentials revenue up 17% y/y $6.7 $5.7 Clinical Solutions revenue up 46% y/y Q4:20 Q4:21 Lab Essential
Slide 9: 2021 Revenue Highlights
2021 Revenue Highlights Revenue by Category ($M) $36.9 Key Highlights $31.3 $6.8 Total revenue up 18% y/y $4.8 Total revenue of $35.4 million, excluding Sample Transport, up 31% y/y $27.2 Lab Essentials revenue up 28% y/y $21.2 Clinical Solutions revenue up 41% y/y 2020 2021 Lab Essentials C
Slide 10: Q4:2021 Income Statement Highlights
Q4:2021 Income Statement Highlights Gross Margin (%)1 Total Opex ($M) 54.8% $9.7 47.0% $4.8 Q4:20 Q4:21 Q4:20 Q4:21 Adjusted EBITDA ($M)2 Diluted EPS ($) $1.6 $0.03 ($3.4) ($0.13) Q4:20 Q4:21 Q4:20 Q4:21 1 Q4:21 gross margin excludes the impact of a $0.2 million, one-time benefit from reversing a po
Slide 11: 2021 Income Statement Highlights
2021 Income Statement Highlights Gross Margin (%)1 Total Opex ($M) 56.7% $29.6 48.9% $13.1 2020 2021 2020 2021 Adjusted EBITDA ($M)2 Diluted EPS ($) $0.16 $7.0 ($0.61) ($7.6) 2020 2021 2020 2021 1 2021 gross margin excludes the impact of a $0.4 million net reserve related to excess Sample Transport
Slide 12: Q4:21 Cash Flow & Balance Sheet Highlights
Q4:21 Cash Flow & Balance Sheet Highlights Free Cash Flow1 ($M) Capital Expenditure ($M) ($1.1) ($10.5) $7.4 $3.5 Q4:20 Q4:21 Q4:20 Q4:21 Cash and Cash Equivalents as of December 31, 2021: $87.5 M 1 Free Cash Flow equals cash provided by (used in) operating activities less purchases of property, pla
Slide 13: 2021 Cash Flow & Balance Sheet Highlights
2021 Cash Flow & Balance Sheet Highlights Free Cash Flow1 ($M) Capital Expenditure ($M) ($3.0) ($28.9) $19.9 $5.5 2020 2021 2020 2021 Cash and Cash Equivalents as of December 31, 2021: $87.5 M 1 Free Cash Flow equals cash provided by (used in) operating activities less purchases of property, plant,
Slide 14: 2022 Guidance
2022 Guidance – Estimate total revenue between $44-48 million, 30% growth y/y at the mid-point as compared to 2021 revenue ex-Sample Transport – Expect approximately 25% growth in Lab Essentials and approximately 60% growth in Clinical Solutions – Will continue investment in 2022 in capacity, sales
Slide 15: Closing Comments
Closing Comments Stephen Gunstream, Chief Executive Officer
Slide 16: Q&A
Q&A
Slide 17: Supplemental Financials and Non-GAAP Reconciliations
Supplemental Financials and Non- GAAP Reconciliations
Slide 18: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (unaudited) (In thousands) For the Three Months Ended December 31, For the Twelve Months Ended December 31, 2021 2020 2021 2020 Net (loss) income – as reported $ (3,647) $ 577 $ (9,8